The Limited Times

Now you can see non-English news...

Cavaleri (Ema), all anti Covid-19 vaccines are valid

2021-06-16T13:18:59.839Z


For the European Medicines Agency (Ema), all four anti Covid-19 vaccines approved in Europe are valid: there is therefore no back-front on AstraZeneca by the European regulatory body, he told ANSA the coordinator of the Ema vaccines task force, Marco Cavaleri (ANSA)


For the European Medicines Agency (

Ema

), all

four

anti Covid-19 vaccines approved in Europe

are valid

: there is therefore no back-front on

AstraZeneca

by the European regulatory body, he told ANSA the coordinator of the EMA vaccines task force, Marco Cavaleri. The data on the risk-benefit ratio are also positive for the other viral vector vaccine, that of

Janssen (Johnson & Johnson)

and for the two vaccines based on messenger RNA (mRna) technology, namely those of

Moderna

and

Pfizer / BioNTech

. And '

being

, then, the

clinical study

of the vaccine company

Curevac

, based in Germany, which could come to the examination of the EMA

towards the end of the summer

: for Europe it could become the fifth anti Covid vaccine and the third in mRna.



"All the vaccines approved by the EMA, including that of AstraZeneca, maintain a

positive risk-benefit ratio

especially in the

elderly and vulnerable

, so they should continue to be used", noted Cavaleri. Ema's position on the AstraZeneca vaccine "has not changed", but of course the

cases of thrombosis

that have so far occurred mainly in young women are under

attention

of the regulatory body. "Cases of thrombosis with thrombosis have emerged, which have been examined by our pharmacovigilance committee" and "in addition, the EMA has conducted

new analyzes

to contextualize the risk of thrombosis in different age groups, by sex and in different epidemiological contexts. ", which made it possible to define how to use the vaccine in the context of vaccination campaigns."

The results are expected in July

.



For young people so far vaccinated with AstraZeneca and awaiting the

second dose

"so far

there is no evidence

that thrombosis cases are associated with the second dose: in the coming weeks we will analyze the available data and take stock of the evidence. To date - observed Cavaleri - the

preliminary data bodes well

".



What can be said about this vaccine is that" it was

approved at the beginning of the year in the population aged 18 and over

in the light of a report and positive risk-benefit, especially for the elderly. "the latter were not included in the initials trials in sufficient numbers, but now there are elements to confirm that" among the population over 60 years the benefits outweigh the risks. "



They continue to collect data on

Janssen's

vaccine as well

following the cases of thrombosis detected in young women in the United States: "it is important to

continue monitoring

, but the position of the EMA confirms that the cost-benefit ratio of this vaccine is positive from 18 years of age".



All four vaccines approved in Europe

continue to be studied

also

to understand if and how much are effective against variants

of the virus SarsCoV2. The

first data are expected "by the summer"

Cavaleri said, and the decision to administer a third dose of the vaccine will also depend on him. It is an issue "on which we are already working with the manufacturers" because "the duration of vaccine protection is not known to date, but preliminary data suggest that it may last over time, for example for a year or more. '.



However this time - he observed - could change the face of the circulation of variants. " Any decision on when and how to give a

third dose

of the vaccine, he added, "will have to be

made on the basis of the data

"on possible cases of infection or disease in people already vaccinated. If the circulation of the variants of the virus should make it necessary to modify the vaccine, it is expected that it will be possible" to obtain authorization from the EMA in a short time ".

Source: ansa

All tech articles on 2021-06-16

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.